Natera’s chief legal officer sells $3.4 million in stock

Daniel Rabinowitz, Secretary and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), a $19.17 billion market cap company showing strong revenue growth of 51.5%, sold 20,372 shares of common stock between June 18 and July 21. The sales, conducted under a pre-arranged 10b5-1 trading plan, fetched prices ranging from $139.29 to $171.4973, totaling approximately $3.4 million. According to InvestingPro analysis, the stock has delivered a robust 31.36% return over the past year.

On June 18, Rabinowitz sold 10,000 shares in multiple transactions, with prices ranging from $170.00 to $170.50. On June 20, he sold 7,630 shares in multiple transactions, with prices ranging from $170.11 to $171.10, and a further 2,278 shares in multiple transactions, with prices ranging from $171.12 to $171.74. On July 21, Rabinowitz sold 464 shares at $139.29 per share to cover tax obligations related to vesting Restricted Stock Units. Currently trading near its 52-week range of $92.14-$183, InvestingPro data indicates the stock is in oversold territory.

Additionally, on July 20, Rabinowitz exercised 856 Restricted Stock Units, which represent the contingent right to receive one share of Natera’s Common Stock each. For comprehensive insider trading analysis and 12 additional ProTips about Natera, visit InvestingPro, where you’ll find detailed research reports and expert insights.

In other recent news, Natera reported its Q1 2025 earnings, exceeding analysts’ expectations with an earnings per share of -$0.50, compared to the anticipated -$0.64. The company’s revenue reached $522 million, representing a 37% increase from the previous year. RBC Capital Markets maintained an Outperform rating for Natera, with a price target of $251, citing strong performance and increased guidance due to accelerated revenue growth. Meanwhile, TD Cowen analysts raised their price target for Natera to $200, highlighting a 13% sales increase, driven by a 5% rise in core sales and additional favorable factors. Natera’s Signatera product saw significant growth, with clinical volumes in Q1 rising to approximately 17,000, a 52% year-over-year increase. Additionally, Medicare expanded coverage for Natera’s Signatera MRD assay, now covering a wider range of cancers. This expansion follows a pan-cancer study presented at the 2025 ASCO Annual Meeting, underscoring the clinical utility of the assay. Leerink Partners reiterated an Outperform rating for Natera, maintaining a price target of $220, following Medicare’s coverage decision for the WGS Signatera assay.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.